Adjunctive therapy in type 1 diabetes — indication assessment
Use alongside insulin in autoimmune diabetes, where the therapeutic target is postprandial excursion, insulin dose or weight rather than endogenous insulin secretion.
§1Assessment
§1.1Definition
Use alongside insulin in autoimmune diabetes, where the therapeutic target is postprandial excursion, insulin dose or weight rather than endogenous insulin secretion.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- Change in HbA1c
- Change in total daily insulin dose
- Time in range on continuous glucose monitoring
- Severe hypoglycaemia
- Diabetic ketoacidosis
§1.3State of the evidence
The Institute assesses 2 compounds in this indication, drawing on 15 trial records and 2 evidence syntheses. [1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2016;375(4):311–322. doi:10.1056/NEJMoa1603827 · PMID 27295427
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.